Expertise in
11
conditions

Kristian W. Pajtler

Heidelberg, BW, DE 
Expertise in
11
conditions
Heidelberg, BW, DE 

Overview

Kristian Pajtler practices practicing medicine in Heidelberg, Germany.

Pajtler is highly rated in 11 conditions, according to our data. Their clinical expertise encompasses Ependymoma, Gliomatosis Cerebri, Glioma, Brain Tumor, and Tissue Biopsy.

They are actively involved in clinical research, co-authoring 169 peer reviewed articles and participating in 1 clinical trial.

Locations

Heidelberg, BW, Germany
Other Locations
Germany
Essen, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Irinotecan, Temozolomide
Study Phase: Phase 1/Phase 2

169 Total Publications

Switching Tracks: Activity of Entrectinib After Progression While on Larotrectinib in Neurotrophin Receptor Tyrosine Kinase-Fused Pediatric High-Grade CNS Tumors.
Switching Tracks: Activity of Entrectinib After Progression While on Larotrectinib in Neurotrophin Receptor Tyrosine Kinase-Fused Pediatric High-Grade CNS Tumors.
Journal: JCO precision oncology
Published: May 14, 2026

Frequently Asked Questions about Kristian W. Pajtler

Is Kristian W. Pajtler a top-rated expert for Ependymoma?

MediFind is an objective health platform that identifies experts based on real-world data. Kristian W. Pajtler is classified as an Elite expert for Ependymoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kristian W. Pajtler participate in research or clinical trials?

Yes. Kristian W. Pajtler has published 169 articles and abstracts on conditions like Ependymoma. You can view a list of Kristian W. Pajtler's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Pajtler's expertise for a condition
ConditionClose
View All 52 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile